| 000 | 01915 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250514000608.0 | ||
| 264 | 0 | _c20010607 | |
| 008 | 200106s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.2001.19.10.2754 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLawrence, J A | |
| 245 | 0 | 0 |
_aPhase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMay 2001 |
||
| 300 |
_a2754-63 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAlitretinoin |
| 650 | 0 | 4 | _aAntigens, Nuclear |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCholesterol _xblood |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKi-67 Antigen |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNuclear Proteins _xisolation & purification |
| 650 | 0 | 4 |
_aTamoxifen _xtherapeutic use |
| 650 | 0 | 4 |
_aTretinoin _xadverse effects |
| 700 | 1 | _aAdamson, P C | |
| 700 | 1 | _aCaruso, R | |
| 700 | 1 | _aChow, C | |
| 700 | 1 | _aKleiner, D | |
| 700 | 1 | _aMurphy, R F | |
| 700 | 1 | _aVenzon, D J | |
| 700 | 1 | _aShovlin, M | |
| 700 | 1 | _aNoone, M | |
| 700 | 1 | _aMerino, M | |
| 700 | 1 | _aCowan, K H | |
| 700 | 1 | _aKaiser, M | |
| 700 | 1 | _aO'Shaughnessy, J | |
| 700 | 1 | _aZujewski, J | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 19 _gno. 10 _gp. 2754-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2001.19.10.2754 _zAvailable from publisher's website |
| 999 |
_c11285461 _d11285461 |
||